EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma

Antonio Mulero-Sánchez iD, Christel F A Ramirez, Aimée du Chatinier, Hui Wang, Sofie J I Koomen, Ji-Ying Song, Marnix H P de Groot, Cor Lieftink, Astrid Bosma, Artur Burylo, Olaf van Tellingen, Roderick L Beijersbergen und 4 weitere

Molecular Oncology · 2023

DOI: 10.1002/1878-0261.13377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Antonio Mulero-Sánchez und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, This work was funded by the American Association for Cancer Research, Lustgarten Foundation, and Stand Up to Cancer as a Pancreatic Cancer Collective New Thera….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver cancer is the fourth most common cause of cancer‐related death worldwide, with hepatocellular carcinoma (HCC) being the main primary malignancy affecting the liver. Unfortunately, there are still limited therapeutic options for HCC, and even the latest advances have only increased the overall survival modestly. Thus, new treatment strategies and rational drug combinations are urgently needed. Reactivation of receptor tyrosine kinases (RTK) has been described as a mechanism of intrinsic resistance to targeted therapies in a variety of cancers, including inhibitors of mTOR. The design of rational combination therapies to overcome this type of resistance is complicated by the notion that multiple RTK can be upregulated during the acquisition of resistance. SHP2, encoded by the gene PTPN11 , acts downstream of virtually all RTK, and has proven to be a good target for small molecule inhibitors. Here, we report activation of multiple RTK upon mTOR inhibition in HCC which, through SHP2, leads to reactivation of the mTOR pathway. We show that co‐inhibition of both mTOR and SHP2 is highly synergistic in vitro by triggering apoptosis . More importantly, the combination is well‐tolerated and outperforms the monotherapies in impairing tumor growth in multiple HCC mouse models. Our findings suggest a novel rational combination therapy for the treatment of HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAnimalsMiceCell Line, TumorTOR Serine-Threonine KinasesReceptor Protein-Tyrosine Kinases

Stichwörter der Autor:innen

SHP2combinationhepatocellular carcinomamTORreceptor tyrosine kinasestherapy

Substanzen

TOR Serine-Threonine KinasesReceptor Protein-Tyrosine Kinases

Autor:innen und Institutionen

  • Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Division of Tumor Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China.
  • Department of Experimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

ORCID-Profile: Antonio Mulero-Sánchez, René Bernards

Förderung

  • National Natural Science Foundation of China
  • This work was funded by the American Association for Cancer Research, Lustgarten Foundation, and Stand Up to Cancer as a Pancreatic Cancer Collective New Thera…

Zitieren

APA

Mulero-Sánchez, A., Ramirez, C. F. A., du Chatinier, A., Wang, H., Koomen, S. J. I., Song, J. Y., de Groot, M. H. P., Lieftink, C., Bosma, A., Burylo, A., van Tellingen, O., Beijersbergen, R. L., Wang, C., Akkari, L., Bernards, R., & Mainardi, S. (2023). Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma. Molecular Oncology. https://doi.org/10.1002/1878-0261.13377

Vancouver

Mulero-Sánchez A, Ramirez CFA, du Chatinier A, Wang H, Koomen SJI, Song JY, et al. Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma. Molecular Oncology. 2023. doi:10.1002/1878-0261.13377

BibTeX
@article{MuleroSnchez2023,
  author = {Mulero-Sánchez, Antonio and Ramirez, Christel F A and du Chatinier, Aimée and Wang, Hui and Koomen, Sofie J I and Song, Ji-Ying and de Groot, Marnix H P and Lieftink, Cor and Bosma, Astrid and Burylo, Artur and van Tellingen, Olaf and Beijersbergen, Roderick L and Wang, Cun and Akkari, Leila and Bernards, René and Mainardi, Sara},
  title = {Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma},
  journal = {Molecular Oncology},
  year = {2023},
  doi = {10.1002/1878-0261.13377}
}
Kostenlos starten →